WebJul 30, 2024 · The pair of assays, Decipher Prostate Biopsy and Decipher Prostate RP, analyze a targeted panel of gene transcripts to guide treatment decision-making at different time points in disease progression. According to Veracyte CFO Rebecca Chambers, the company processed approximately 7,000 tests during the second quarter of this year. ... WebFeb 3, 2024 · Decipher Biosciences grew its 2024 total revenue by more than 130% to approximately $39 million to $40 million, compared to $16.5 million in 2024. This …
Veracyte Announces Seven Abstracts for Its Decipher Urologic …
WebNov 30, 2024 · Decipher Biosciences is focused on improving patients’ lives on their journey with prostate and bladder cancer. The firm is one of the few genetic testing companies that offers diagnoses on urologic cancer. While the prostate genetic diagnoses are offered exclusively for men, genetic bladder diagnoses can be used for both men and women. WebApr 4, 2016 · Decipher® Prostate Cancer Classifier (GenomeDX Biosciences, Inc.)5 o According to the manufacturer, the Decipher test is a tissue-based tumor genomic test that predicts the probability of metastasis within 5 years of RP, and provides an independent assessment of tumor aggressiveness, information that hartman\u0027s grocery ottawa
Advances in Salvage Radiotherapy for Prostate Cancer: Dose, …
WebApr 12, 2024 · Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for … WebMar 5, 2024 · The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate foe active surveillance, needs … WebOct 10, 2024 · Oncotype Dx Genomic Prostate Score and Decipher are multimarker tests that are specific to prostate cancer, are commercially available, and are recommended by expert groups for risk stratification in clinically localized disease and, in the case of Decipher, for selection of males for postprostatectomy radiation therapy (RT). ... hartman\u0027s haven hickory nc